Market Overview

Jefferies Updates Price Targets In Global Pharma, Sees 'Rich Catalyst Environment' Ahead

Jefferies Updates Price Targets In Global Pharma, Sees 'Rich Catalyst Environment' Ahead

There are a number of catalysts on the horizon for global pharma stocks, but Jefferies has dialed back expectations for a number of stocks in the space. In a new report, analyst Jeffrey Holford has updated the firm’s outlook and price targets for the biggest names in the pharma space.

Despite lowering a number of price targets, Jefferies is excited about the potential for top pick AbbVie Inc (NYSE: ABBV).

“We expect that the PTAB decision whether or not to institute IPR on the CHRS challenge to ABBV’s ‘135 RA closing patent will be one of the most significant catalysts in the near future,” Holford explained.

Related Link: User Questions When Bill Ackman Had Access To Valeant Earnings

Jefferies predicts roughly a $9/share gain for AbbVie’s stock in the case of denial and a $3/share decline in the case of institution.

Jefferies maintains a Buy rating and $90 price target for AbbVie.

It's Not All About AbbVie

In addition, the firm has reduced price targets for the following U.S.-listed stocks:

  • Abbott Laboratories (NYSE: ABT): to $44
  • Eli Lilly and Co (NYSE: LLY): to $100
  • Johnson & Johnson (NYSE: JNJ): to $108)

Jefferies also upped price targets for these names:

  • Bristol-Myers Squibb Co (NYSE: BMY): to $76
  • Pfizer Inc (NYSE: PFE): to $41)

Jefferies is currently most bullish on Buy rated names AbbVie, Abbott, Eli Lilly, Novartis AG (ADR) (NYSE: NVS), Pfizer, Roche Holding Ltd. (ADR) (OTC: RHHBY) and Zoetis Inc (NYSE: ZTS).

Finally, Holford sees the pharma M&A environment “heating up” and believes that a number of the big players are likely interested in Medivation Inc (NASDAQ: MDVN).

Disclosure: The author holds no position in the stocks mentioned.

Latest Ratings for ABBV

Sep 2019UpgradesNeutralBuy
Sep 2019UpgradesNeutralBuy
Sep 2019MaintainsOverweight

View More Analyst Ratings for ABBV
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Long Ideas Health Care Price Target Top Stories Analyst Ratings Trading Ideas Best of Benzinga


Related Articles (ABT + ABBV)

View Comments and Join the Discussion!

Decreasing Visibility: BTIG Downgrades EPRS To Neutral

Former Dallas Fed President Is Worried About Insurance